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The ATP-binding cassette transporter A1 regulates
phosphoantigen release and Vg9Vd2 T cell
activation by dendritic cells
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Vg9Vd2 T cells are activated by phosphoantigens, such as isopentenyl pyrophosphate (IPP),
which is generated in the mevalonate pathway of antigen-presenting cells. IPP is released in
the extracellular microenvironment via unknown mechanisms. Here we show that the
ATP-binding cassette transporter A1 (ABCA1) mediates extracellular IPP release from
dendritic cells (DC) in cooperation with apolipoprotein A-I (apoA-I) and butyrophilin-3A1. IPP
concentrations in the supernatants are sufﬁcient to induce Vg9Vd2 T cell proliferation after
DC mevalonate pathway inhibition with zoledronic acid (ZA). ZA treatment increases ABCA1
and apoA-I expression via IPP-dependent LXRa nuclear translocation and PI3K/Akt/mTOR
pathway inhibition. These results close the mechanistic gap in our understanding of
extracellular IPP release from DC and provide a framework to ﬁne-tune Vg9Vd2 T cell
activation via mevalonate and PI3K/Akt/mTOR pathway modulation.
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g9Vd2 T cells are activated by phosphoantigen that
are generated in the mevalonate and non-mevalonate
pathway of microbial pathogens. The mevalonate pathway
of mammalian cells also generates phosphoantigens such as
isopentenyl pyrophosphate (IPP), which activate Vg9Vd2 T cells
almost as efﬁciently as microbial phosphoantigens1,2. Vg9Vd2 T
cells recognize tumour cells that release mevalonate pathway–
derived phosphoantigens as IPP1. In addition, Vg9Vd2 T cells are
speciﬁcally activated by antigen-presenting cells, such as dendritic
cells (DC), particularly when intracellular IPP generation is
boosted with zoledronic acid (ZA), which is an inhibitor of the
farnesyl pyrophosphate synthase (FPPS) in the mevalonate
pathway3–5. How IPP is released in the extracellular
microenvironment and delivered to Vg9Vd2 T cells is unknown.
CD277/butyrophilin-3A1 (BTN3A1) is a type I glycoprotein
that has a central function in phosphoantigen-induced Vg9Vd2 T
cell activation (reviewed in Harly et al.)4. Two mechanisms have
been hypothesized: the ‘allosteric model’ proposed by Harly et al.6
and ‘antigen-presenting model’ by Vavassori et al.7 In the ﬁrst
model, the interaction between intracellular phosphoantigens and
the intracellular B30.2 domain of BTN3A1 induces
conformational changes of the extracellular domain, which are
sensed by Vg9Vd2 T cells and cause their activation. In
Vavassori’s model, intracellular phosphoantigens are exported
to the extracellular microenvironment by an unidentiﬁed plasma-
membrane-associated transporter and presented to Vg9Vd2
T cells by the BTN3A1 extracellular domain. Most data
currently available are in favour of the allosteric model8,9, but it
is currently unknown whether BTN3A1 is also involved in
extracellular phosphoantigen release.
Ecto-F1-ATPase and apolipoprotein A-I (apoA-I) are addi-
tional important molecules involved in Vg9Vd2 T cell
activation10–13. F1-ATPase can bind both apoA-I and tripho-
sphoric acid 1-adenosin-59-yl ester 3-(3-methylbut-3-enyl) ester
(ApppI), which is an adenylated derivative of IPP that
accumulates in ZA-treated cells. IPP can be released from
ApppI by nucleotide pyrophosphatase causing the activation of
Vg9Vd2 T cells11. Soluble apoA-I can improve Vg9Vd2 T cell
recognition of tumour cells, which overproduce IPP (that is, after
ZA treatment), whereas low levels of circulating apoA-I in
chronic inﬂammation are associated with a low activation state of
Vg9Vd2 T cells11–13.
apoA-I is required for the assembly of nascent high-density
lipoprotein (HDL) particles, which mediate the reverse
cholesterol transport14. apoA-I binds the extracellular domain
of the ATP-binding cassette transporter A1 (ABCA1). ABCA1
is a member of the ABC transmembrane transporter family,
which is abundant in the liver, the gastrointestinal tract and
macrophages. ABCA1 efﬂuxes cholesterol and phospholipids to
lipid-poor/lipid-free apoA-I. During the HDL assembly process,
ABCA1 cooperates with the ATP-binding cassette transporter
G1 (ABCG1) and the scavenger receptor-BI (SR-BI), which
are two transporters that are involved in the delivery of
cholesterol and choline-rich phospholipids to HDL14.
Interestingly, ABCA1 also efﬂuxes a-tocopherol15, which is a
molecule that contains multiple isoprenoid units; however, it has
never been reported whether ABCA1 or any other ABC
transporter are involved in the extracellular release of IPP or
other isoprenoids.
On the basis of these observations, here we test the hypothesis
that ABCA1, apoA-I, and BTN3A1 are involved in extracellular
IPP release. We demonstrate that ABCA1, in cooperation with
apoA-I and BTN3A1, has a major function in extracellular IPP
release from ZA-treated DC. Supernatants from ZA-treated DC
contain sufﬁcient IPP to induce Vg9Vd2 T cell proliferation
even after removal of ZA-treated DC. These data show that
ABCA1 has a function that may alter our understanding of the
relationship between lipid metabolism and immune function.
Results
Soluble IPP-induced Vc9Vd2 T cell proliferation. Figure 1a
shows the proliferation of Vg9Vd2 T cells after 7-day stimulation
of peripheral blood mononuclear cells (PBMC) from healthy
donors with supernatants obtained from autologous monocytes
(CD14þ ) or DC that are left untreated or treated with ZA for
24 h. As previously reported, supernatants from ZA-treated DC
induced signiﬁcant Vg9Vd2 T cell proliferation3.
In a second set of experiments, DC were incubated for
24 h with or without ZA and washed to clear supernatants
from any residual ZA. Washed DC were re-plated for an
additional 24 and 48 h in the absence of any other treatment,
and intracellular and extracellular IPP levels were evaluated
as previously reported (Fig. 1b)3. ZA-treated washed DC released
signiﬁcant amounts of IPP for the ﬁrst 24 h and their
supernatants induced a dose-dependent proliferation of
Vg9Vd2 T cells (Fig. 1c).
The same set of experiments was performed using unmanipu-
lated or DC-like cells that were generated from the acute monocytic
leukaemia THP-1 cell line (DCTHP1) and the histiocytic lymphoma
U937 cell line (DCU937)16–18. DCTHP1 and DCU937 have
been shown to perform in many functional assays as well as
the conventional counterparts generated from CD14þ cells.
ZA-treated THP-1 cells and DCTHP1 produced signiﬁcant
amounts of intracellular IPP, such as ZA-treated DC (Fig. 1b),
whereas U937 cells and DCU937 produced lower amounts,
which were unaffected by ZA treatment (Fig. 1d). Extracellular
IPP release showed an opposite pattern: THP-1 cells and DCTHP1
did not release extracellular IPP even after ZA treatment, whereas
ZA-treated DCU937 released intermediate levels (Fig. 1d) that were
similar to the levels released by ZA-treated DC (Fig. 1b). The
different IPP concentrations in the supernatants translated into
a different ability to induce Vg9Vd2 T cell proliferation (Fig. 1e).
Increased ABCA1 and apoA-I expression after ZA treatment.
ABCA1, ABCG1 and SR-BI expression were investigated under
baseline conditions and after ZA treatment (Fig. 2a). THP-1,
U937 and CD14þ cells exhibited no detectable ABCA1 or
ABCG1 levels, irrespective of ZA treatment. ZA-treated DCTHP1
also exhibited no expression, whereas untreated DCU937 and
DC already exhibited detectable ABCA1 expression, which
increased after ZA treatment. DC were the only cells to show
detectable ABCG1 expression, which was upregulated by ZA
treatment. SR-BI expression was uniformly detectable in all cell
preparations and unaffected by ZA treatment. Pooled data with
statistical analyses are shown in Fig. 2b.
apoA-I binds to the extracellular domain of ABCA1 to load
cholesterol and phospholipids that are released in the reverse
cholesterol transport. apoE is also involved in the same process but
it binds to ABCG1. We performed a matrix-assisted laser desorption
ionization-time-of-ﬂight/mass spectrometry (MALDI-TOF/MS)
analysis to investigate whether apoA-I and apoE were present in
the supernatant of CD14þ cells and DC (Supplementary Table 1).
Two bands of 36.1 and 30.7 kD, which correspond to apoE
and apoA-I, were identiﬁed (Fig. 2c, left; Supplementary Fig. 1;
Supplementary Table 1). ZA treatment did not modify apoE levels,
whereas it increased apoA-I expression (Fig. 2c, right). These data
indicate that ZA-induced mevalonate pathway inhibition increases
the extracellular release of both IPP and apoA-I in both CD14þ
and DC.
To further explore the relationship among IPP, apoA-I, and
apoE, extracellular IPP was quantiﬁed in the supernatant of
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untreated and ZA-treated THP-1 cells, U937 cells, CD14þ cells,
DCTHP1, DCU937, and DC after incubation with recombinant
human apoA-I and apoE and pulsing with [14C]-IPP. As shown
in Fig. 2d, exogenously added apoA-I and apoE promoted
extracellular IPP release only in cells with detectable ABCA1
expression, that is, untreated and ZA-treated DCU937 and DC.
To further build on the relationship between IPP and ABCA1,
we correlated intracellular and extracellular IPP levels with ABCA1,
ABCG1 and SR-B1 expression in a series of haematologically
derived neoplastic and non-neoplastic cells (Supplementary
Fig. 2A, Supplementary Fig. 2B). A strong correlation was detected
between ABCA1 levels and extracellular IPP levels (r2¼ 0.98),
whereas no correlation between intracellular IPP levels and ABCA1
levels was identiﬁed (Supplementary Fig. 2C). ZA treatment
upregulated ABCA1 expression only in cells with detectable
ABCA1 under baseline conditions, such as the myeloma cell line
SKMM1, primary multiple myeloma cells (CD138þ MM) and
bone marrow stromal cells (BMSC) derived from multiple
myeloma patients (Supplementary Fig. 3).
To eliminate the possibility that ZA-induced ABCA1 upregula-
tion was not merely due to modiﬁcations of cholesterol content in
the plasma-membrane and associated with non-speciﬁc changes in
other membrane proteins, we compared the expression levels and
activities of unrelated transporters and channels in untreated and
DC treated with ZA and/or simvastatin. Simvastatin is a selective
inhibitor of 3-b-hydroxy-b-methylglutaryl coenzyme A reductase
(HMGR) upstream to FPPS in the mevalonate pathway that
strongly reduces cholesterol synthesis3. The results in Fig. 3
indicate that neither the expression nor the activity of other ABC
transporters that are involved in cholesterol and lipid metabolites
efﬂux (ABCA2, ABCB1, ABCC1, ABCC2, ABCC3, ABCC4,
ABCC5, ABCC6, ABCG2, ABCG4, ABCG5, ABCG8), phosphate
transporters potentially involved in pyrophosphate transport
(PiT-1/SLC20A1, PiT-2/SLC20A2, NPT2A/SLC34A1), and other
ubiquitous and unrelated pumps or channels (Naþ /Kþ -ATPase,
Naþ /Hþ exchanger 1/NHE1, Cl /HCO3 transporter/SLC4A1)
were modiﬁed by ZA or simvastatin treatment.
IPP is released by ABCA1 in cooperation with BTN3A1.
Probucol is a functional ABCA1 inhibitor19. Probucol incubation
of untreated and ZA-treated DC for 24 h marginally increased
intracellular IPP levels and completely abrogated ZA-induced
extracellular IPP release (Fig. 4a).
To conﬁrm the role of ABCA1, siRNA were employed
to silence Abca1 in untreated and ZA-treated DC. The efﬁcacy
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Figure 1 | Vc9Vd2 T cell proliferation is induced by extracellular IPP. (a) Vg9Vd2 T cell proliferation after 7-day PBMC stimulation with ZA or
supernatant (SN) retrieved from untreated (ZA-) and ZA-treated (ZAþ ) CD14þ cells and DC. Supernatant from ZA-treated DC induced signiﬁcantly
higher Vg9Vd2 Tcell proliferation than PBMC stimulation with supernatant from ZA-treated CD14þ cells (*Po0.05; Wilcoxon–Mann–Whitney). The bars
represent the mean value±s.e.m. of eight experiments. (b) Intracellular IPP concentrations in untreated (ZA-) and ZA-treated (ZAþ ) washed DC
(w-DC) and extracellular IPP concentrations in corresponding SN after washing and incubation for 24 and 48 h without further ZA stimulation. ZA-treated
w-DC released signiﬁcant IPP amounts for 24 h after ZA removal. The bars represent the mean value±s.e.m. of ten experiments (*Po0.05; *Po0.001;
ANOVA). (c) Vg9Vd2 T cell proliferation after 7-day PBMC stimulation with ZA or with serial dilutions of supernatants (w-SN) retrieved from untreated
(ZA-) and ZA-treated (ZAþ ) w-DC. The bars represent the mean value±s.e.m. of eight experiments. (d) Intracellular and extracellular IPP levels
generated in untreated (ZA-) and ZA-treated (ZAþ ) THP-1 cells, DCTHP1, U937 cells and DCU937. ZA-treated THP-1 cells and DCTHP1 generated high
amounts of intracellular IPP, which was not released in the supernatant. Conversely, ZA-treated DCU937 released extracellular IPP amounts that were close
to the extracellular IPP amounts released by ZA-treated DC. Bars represent the mean value±s.e.m. of eight experiments (*Po0.05; ANOVA). (e) Vg9Vd2
Tcell proliferation after 7-day PBMC stimulation with supernatant obtained from untreated (ZA-) and ZA-treated (ZAþ ) THP-1 cells, DCTHP1, U937 cells
and DCU937. Only SN from ZA-treated DCU937 induced Vg9Vd2 T cell proliferation. The bars represent the mean value±s.e.m. of ﬁve experiments
(*Po0.05; Wilcoxon–Mann–Whitney). ANOVA, analysis of variance.
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and speciﬁcity are shown in Fig. 4b. As expected, Abca1-silencing
marginally increased intracellular IPP generation, whereas it
completely abrogated ZA-induced extracellular IPP release
(Fig. 4c). The inability to induce Vg9Vd2 T cell proliferation
provided the functional demonstration that supernatants from
ZA-treated Abca1-silenced DC were devoid of IPP (Fig. 4d).
These results indicate that ABCA1 has a major role in the
extracellular IPP release from ZA-treated DC.
BTN3A1 has been reported to be involved in the phosphoanti-
gen-induced activation and recognition of target cells by Vg9Vd2
T cells5,6. To explore any relationship between ABCA1 and
BTN3A1, BTN3A1 expression was investigated by ﬂow cytometry
in CD14þ cells, DCTHP1, DCU937, and DC without detecting any
difference under baseline conditions or after ZA treatment
(Supplementary Fig. 2D). BTN3A1 and ABCA1 were co-
immunoprecipitated in DCU937 and DC, which were the only
cells to express detectable amounts of ABCA1 (Fig. 5a). ZA
treatment increased ABCA1 expression but did not modify
BTN3A1 expression. The physical interaction between ABCA1
and BTN3A1 was conﬁrmed in DCU937 and DC by the proximity
ligation assay (PLA) (Fig. 5b). Next, we tested the presence of
interactions between apoA-I and ABCA1 or BTN3A1. After
crosslinking of apoA-I to cell surface proteins and immuno-
precipitation with anti-apoA-I antibody, we found that apoA-I
and ABCA1 are physically associated as previously reported20,
whereas no interaction was detected between apoA-I and
BTN3A1 (Fig. 5c).
To determine the reciprocal contributions to extracellular IPP
release, BTN3A1 and ABCA1 were alternatively or concurrently
silenced in untreated and ZA-treated DC. The efﬁcacy
and speciﬁcity of siRNA are shown in Fig. 5d: untreated
DC (ZA ) expressed detectable levels of ABCA1, which further
increased in ZA-treated DC (ZAþ ) and disappeared in untreated
and ZA-treated Abca1-silenced and Abca1þBtn3a1-silenced
DC, whereas ABCA1 expression was not suppressed in
Btn3a1-silenced DC. To determine whether IPP was physically
associated with ABCA1, DC were treated as shown in Fig. 5d,
radiolabelled with 1 mM [14C]-IPP, and chemically crosslinked
after extensive washing. ABCA1 was immunoprecipitated by
plasma-membrane extracts, resolved by sodium dodecyl sulfate–
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Figure 2 | ZA treatment increases ABCA1 and apoA-1 expression. (a) Western blot analysis of ABCA1, ABCG1 and SR-BI expression in untreated
(ZA-) and ZA-treated (ZAþ ) THP-1 cells, U937 cells, CD14þ cells and corresponding DC subsets (DCTHP1, DCU937, DC). ABCA1 was already
detectable in DCU937 and DC and its expression was upregulated by ZA. b-tubulin was employed to check the equal protein loading per lane. The
results are obtained from one representative experiment of three experiments. (b) Pooled data obtained by densitometric analysis with ImageJ software
(http://imagej.nih.gov/ij/). The results are expressed as arbitrary units (THP-1 cells and DCTHP1, n¼ 3; U937 cells and DCU937, n¼ 3; CD14þ cells and
DC, n¼ 14) (***Po0.001; ANOVA). (c) Supernatants from untreated (ZA-) or ZA-treated (ZAþ ) CD14þ cells and DC were resolved by SDS–PAGE and
stained with Coomassie brilliant blue. A concentration of 1 mgml 1 recombinant human apoE or apoA-I were employed as standards. Densitometric
analyses of bands identiﬁed as apoE or apoA-I by MALDI-TOF/MS were performed with ImageJ software. The results are expressed as arbitrary units. The
gel is representative of one out of the three experiments (*Po0.05, ***Po0.001; ANOVA). (d) Extracellular IPP released in the supernatants retrieved from
untreated (ZA-) or ZA-treated (ZAþ ) CD14þ cells, U937 cells, THP-1 cells and corresponding DC subsets (DC, DCU937, DCTHP1) in the absence (CTRL)
or presence of human recombinant 1 mgml 1 apoA-I or apoE added during the last 24 h of incubation. apoA-I and apoE increased the IPP release in
DC and DCU937 but did not increase the IPP release in DCTHP1. The bars represent the mean value±s.e.m. of three experiments (**Po0.01; ANOVA).
ANOVA, analysis of variance. MALDI-TOF/MS, matrix-assisted laser desorption ionization-time-of-ﬂight/mass spectrometry. SDS-PAGE: sodium dodecyl
sulfate-polyacrilammide gel electophoresis.
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polyacrylamide gel electrophoresis (SDS–PAGE) and probed with
an anti-ABCA1 antibody that recognizes the N-terminal extra-
cellular loop (Fig. 5e, left) or subjected to autoradiography
(Fig. 5e, right). As internal control, biotinylated plasma-
membrane extracts from ZA-treated DC were subjected to
limited digestion to obtain distinct extracellular and intracellular
ABCA1 fragments21,22. Autoradiography showed a positive signal
in untreated DC coincidental with the expected ABCA1
molecular weight, which was increased in ZA-treated DC. The
radioactive signal was still present in Btn3a1-silenced DC,
whereas it was not detectable in Abca1-silenced and Abca1/
Btn3a1-silenced DC. In dithiothreitolþ trypsin-treated DC, the
radioactive signal was coincidental with the 100 kDa band and, to
a lesser extent, with the 150 kDa band, which suggests that
IPP is physically associated with the N-terminal extracellular
domain of ABCA1.
The functional consequences of Abca1-silencing
and Btn3a1-silencing are shown in Fig. 5f,g. Minimal variations
of extracellular IPP levels were induced when Abca1 and/or
Btn3a1 were silenced in the absence of ZA-treatment (Fig. 5f).
Conversely, ZA-treated Abca1-silenced DC showed a signiﬁcant
reduction in the ability to release extracellular IPP, whereas
ZA-treated Btn3A1-silenced DC were only marginally affected.
When both genes were silenced, further reduction in extracellular
IPP release was observed (Fig. 5f). As expected, Vg9Vd2 T cell
proliferation induced by supernatants from Abca1- and/or
Btn3A1-silenced ZA-treated DC matched the extracellular
IPP concentrations (Fig. 5g). These data indicate that ABCA1
plays a major role in extracellular IPP release; this function is
facilitated by physical interactions with IPP, apoA-I and
BTN3A1.
ZA increases IPP efﬂux via LXRa-mediated Abca1 activation.
Simvastatin inhibits the mevalonate pathway upstream to FPPS3.
As expected, simvastatin decreased extracellular IPP release in
both untreated and ZA-treated DC (Fig. 6a). Interestingly,
simvastatin also reduced ABCA1 (Fig. 6b) and apoA-I
expression (Fig. 6c). These data conﬁrm the close relationship
between the mevalonate pathway, ABCA1, apoA-I and
extracellular IPP release.
ABCA1 and apoA-I expressions are controlled by the liver X
receptor (LXR)/retinoic acid X receptor (RXR) transcription
factor receptor family23,24. We investigated whether ZA and
simvastatin regulated ABCA1 and apoA-I expression via these
transcription factors. Untreated DC expressed both LXRa/b
and RXR in nuclear extracts (Fig. 6d). ZA treatment increased
LXRa protein levels, whereas LXRb and RXR intracellular
distribution was unaffected (Fig. 6d). LXRa bound to Abca1
and apoA-I promoters was increased (Fig. 6e), leading
to increased Abca1 and apoA-I mRNA levels (Fig. 6f). These
ZA-induced effects were neutralized by simvastatin (Fig. 6d–f).
These data indicate that ZA-induced LXRa activity is crucial to
increase ABCA1 and apoA-I expression in DC and promotes
extracellular IPP release.
To reinforce the role of LXRa, the experiments mentioned
above were repeated using THP-1 cells, which are unable to
release extracellular IPP, even after DC differentiation and ZA
treatment. Unlike DC, LXRa and LXRb failed to translocate into
the nucleus after ZA treatment in THP-1 cells and DCTHP1
(Supplementary Fig. 4A). As expected, Abca1 and apoA-I mRNA
levels remained unchanged by ZA treatment (Supplementary
Fig. 4B). These data conﬁrm that LXRa is critical to induce
Abca1 and apoA-I transcription and protein expression after
ZA-induced IPP accumulation.
To determine whether ZA or IPP was responsible for LXRa
activation, genomic DNA was extracted from DC and challenged
with increasing ZA and IPP concentrations in the presence of
the human recombinant LXRa transcription protein. Only IPP
was able to induce a dose-dependent LXRa binding to the LXR
responsive element (LRE) in the Abca1 promoter (Fig. 6g).
Optimal LXRa activation was induced by 500 pM IPP, which
falls in the range of concentrations detected in the supernatants of
ZA-treated DC (Fig. 6g). We tested whether other isoprenoids
generated in the mevalonate pathway, such as FPP and GGPP,
can also induce LXRa activation and we found that the former
had no effect, whereas the latter downregulated LXRa activation
(Supplementary Fig. 5) as previously reported25.
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control of equal protein loading. The blots are representative of one out of the three experiments. (b) Activities of the indicated plasma-membrane-
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Next, we investigated whether ZA and/or IPP also increased
the enzyme activity of ABCA1 in addition to its expression.
Identical aliquots of ABCA1 were immunopuriﬁed from the
plasma membrane of DC and incubated with increasing
concentrations of ZA (Supplementary Fig. 6A) or IPP (Supple-
mentary Fig. 6B). The experimental conditions were established
to enable any change in ATPase activity to be referred to
differences in enzyme activity instead of protein expression. The
results indicate that neither ZA nor IPP were able to directly
upregulate ABCA1 ATPase-activity (Supplementary Fig. 6A,B).
Next, we compared the ATPase activity of ABCA1 immunopur-
iﬁed from the plasma membrane of untreated and ZA-treated
CD14þ cells and DC. Untreated CD14þ cells exhibited the
lowest ATPase activity, which remained unaffected by ZA
treatment, whereas untreated DC revealed intermediate values,
which almost doubled in ZA-treated DC (Supplementary
Fig. 6C). The results suggest that the increased ATPase activity
in ZA-treated DC is more likely due to increased ABCA1 protein
levels than to the direct effect exerted by ZA or IPP on its
enzymatic activity.
PI3K/AkT/mTOR pathway regulates IPP release via LXRa/Abca1.
Akt suppresses cholesterol efﬂux by the activation of the
mammalian target of rapamycin (mTOR) complex 1 TORC1,
whereas the inhibition of mTORC1 by rapamycin promotes
cholesterol efﬂux to apoA-I in an ABCA1-dependent manner26.
The phosphoinositide 3-kinase (PI3K)/Akt/mTOR signalling
pathway is also regulated by the Ras prenylation state, which is
dependent on the mevalonate pathway in cancer cells and
activated T cells27,28. To investigate the involvement of the
PI3K/Akt/mTOR signalling pathway in ABCA1/apoA-I-mediated
extracellular IPP release, DC were incubated with speciﬁc PI3K
(LY294002) and mTOR (rapamycin) inhibitors (refer to Methods
and Supplementary Fig. 7 for technical details). Untreated
DC showed detectable phosphorylation activity of both Akt
and mTOR, which was very effectively blocked by ZA treatment.
Akt and mTOR phosphorylation activities were fully recovered by
simvastatin treatment in ZA-treated DC (Fig. 7a), although
simvastatin also induces intracellular isoprenoid deprivation
and Ras deprenylation29,30. A possible explanation is that
isoprenoid deprivation recovers the activity of the PI3K/Akt/
mTOR pathway via induction of the endoplasmic reticulum (ER)
stress and unfolded protein responses (UPR), as previously
reported31. In line with this hypothesis, we have demonstrated
that several ER-stress-related genes are signiﬁcantly upregulated
in ZAþ simvastatin-treated compared with untreated DC
(Supplementary Data 1), as previously reported with ZA or
simvastatin in other cell types32,33.
PI3K and mTOR inhibitors mimicked the effect of ZA by
signiﬁcantly increasing nuclear LXRa protein levels (Fig. 7b),
LXRa transcriptional activity (Fig. 7c), and ABCA1 and apoA-I
protein expression (Fig. 7d). Unlike ZA, LY294002 and
rapamycin did not increase intracellular IPP levels as these
inhibitors do not target the mevalonate pathway (Fig. 7e, left).
However, both inhibitors increased extracellular IPP release
as they upregulated ABCA1 and apoA-I protein expression.
However, LY294002 and rapamycin did not achieve ZA-induced
extracellular IPP values as they did not induce intracellular IPP
accumulation (Fig. 7e, right).
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Figure 4 | ABCA1 has a pivotal function in extracellular IPP release. (a) Intracellular and extracellular IPP levels generated by untreated (ZA-) and
ZA-treated (ZAþ ) DC incubated for 24 h in fresh medium (CTRL) or with 10mM probucol to inhibit ABCA1 function. Probucol marginally increased
intracellular IPP but signiﬁcantly decreased extracellular IPP release in ZA-treated DC (**Po0.01; ANOVA). The bars represent the mean±s.e.m.
of four experiments. (b) Western blot analysis of ABCA1 expression in untreated (ZA-) and ZA-treated (ZAþ ) DC after Abca1-silencing with siRNA
(scrambled [scr] non-targeting siRNA; siAbca1: Abca1-silencing siRNA). The blots are representative of one out of the three experiments. b-tubulin was
employed as the control of equal protein loading. (c) Intracellular and extracellular IPP levels in DC incubated for 48 h in fresh medium (CTRL) or in the
presence of scr or Abca1-silencing siRNA (siAbca1). ZA (1 mM) was added in the last 24 h. Extracellular IPP release is signiﬁcantly lower in Abca1-silenced
ZA-treated DC. Bars represent the mean±s.e.m. of six experiments (**Po0.01; ***Po0.001; ANOVA). (d) Vg9Vd2 T cell proliferation after 7-day PBMC
stimulation with supernatants from DC treated as reported in c. Supernatant from Abca1-silenced ZA-treated DC is unable to induce Vg9Vd2 T cell
proliferation (**Po0.01; Wilcoxon–Mann–Whitney). The bars represent the mean±s.e.m. of six experiments. ANOVA, analysis of variance.
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Discussion
In this study, we conﬁrm that soluble IPP can induce Vg9Vd2 T
cell activation3,34 and demonstrate that the plasma-membrane-
associated transporter ABCA1 plays a major role in the
extracellular IPP release from ZA-treated DC and other cells.
apoA-1 and BTN3A1 are also important contributors to this
process, which ultimately causes the activation of Vg9Vd2 T cells.
Although other metabolites downstream to IPP can also activate
Vg9Vd2 T cells (that is, DMAPP, GPP, FPP and GGPP)35,
none of these molecules achieved mitogenic concentrations
in untreated DC and their levels further decreased after
ZA treatment. These data exclude a contribution of these
molecules in ZA-induced Vg9Vd2 T cell activation.
Cells that are unable to release extracellular IPP in baseline
conditions or after ZA-induced intracellular IPP accumulation do
not express ABCA1; contrariwise, cells with a high capacity to
release intracellular IPP express ABCA1 and further up-regulate
its expression after ZA treatment. IPP is physically associated
with the N-terminal extracellular domain of ABCA1 and this
association is strengthened in ZA-treated cells that have increased
intracellular ABCA1 and IPP levels.
ABCA1 upregulation by ZA treatment is associated with
an increased apoA-1 concentration in the supernatants. The
mutual interaction between ABCA1 and apoA-1 was conﬁrmed
by the ability of exogenously added apoA-I to facilitate
extracellular IPP release, but only in cells that already
express ABCA1 in baseline conditions or after ZA treatment.
We cannot exclude a priori that other transporters are involved
in IPP efﬂux. However, the unique relationship between
ABCA1 upregulation and intracellular IPP accumulation was
corroborated by the observation that ZA and simvastatin
treatment, which increase IPP and decrease IPP respectively, do
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Figure 5 | ABCA1 interactions with BTN3A1, apoA-I and IPP. (a) ABCA1 and BTN3A1 co-immunoprecipitate in untreated and ZA-treated DCU937 and
DC but not in CD14þ cells, and ZA treatment does not modify BTN3A1 expression. Pancadherin is employed as a control of equal protein loading
(one out of three blots). (b) PLA of ABCA1-BTN3A1 interaction by confocal laser-scanning microscopy (ocular lens:  10; objective: 63). Ctrl: cells
without primary antibodies. Scale bar, 10mm; blue: nuclear staining (DAPI); green: ABCA1/BTN3A1 interaction (one out of the three experiments).
(c) apoA-I is physically associated with ABCA1, not with BTN3A1. The expected molecular weight of apoA-I, ABCA1/apoA-I and BTN3A1/apoA-I are shown
(one out of the three experiments). (d) ABCA1 and BTN3A1 expression in DC after incubation with siRNA for Abca1 (siABca1), Btn3a1 (siBtn3a1) or with
scrambled non-targeting siRNA (scr). b-tubulin was employed as control of equal protein loading (n¼ 3). (e) IPP is physically associated with ABCA1 in
untreated and ZA-treated DC. The two bands of 150 and 100 kDa in the dithiothreitol (DTT)- and trypsin-treated DC lane are detected with an antibody
speciﬁc for the N-terminal extracellular loop of ABCA1 in immunoblotting (IB; left). Autoradiography signal of the IPP-ABCA1 interaction (right).
Pancadherin is employed as a control of equal protein loading (one out of three experiments). (f) Extracellular IPP release in Abca1- and/or Btn3a1-silenced
DC left untreated (ZA-) or after ZA treatment (ZAþ ). The bars represent the mean±s.e.m. of three experiments (**Po0.001, Wilcoxon–Mann–
Whitney). (g) Vg9Vd2 Tcell proliferation after 7-day PBMC stimulation with supernatants from Abca1- and/or Btn3a1-silenced DC. The bars represent the
mean±s.e.m. of three experiments (**Po0.01; Wilcoxon–Mann–Whitney).
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not modify the expression of other ABC transporters, phosphate
transporters or other ubiquitous and unrelated pumps or
channels. These results also eliminated the possibility that
ABCA1 expression is upregulated merely because the cholesterol
content of plasma membranes or the intracellular concentration
of other mevalonate pathway-related metabolites are modiﬁed by
ZA or simvastatin.
The experiments in which ABCA1 was functionally inhibited
with probucol, or protein expression speciﬁcally silenced with
siRNA, provided direct evidence that ABCA1 plays a major role
in extracellular IPP release. Both treatments only slightly
increased intracellular IPP concentrations in untreated and
ZA-treated DC, probably because downstream enzymes in the
mevalonate pathway like IPP isomerase and prenyl transferases
intervene to handle IPP accumulation in the absence of ABCA1
upregulation. More importantly, probucol and Abca1-silencing
abrogated extracellular IPP release. IPP deprivation in the
supernatants from ABCA1-inhibited DC was functionally
conﬁrmed by the inability to induce Vg9Vd2 T cell proliferation.
BTN3A1 is also involved in extracellular IPP release. BTN3A1
is an immunoglobulin superfamily protein playing a key role in
Vg9Vd2 T cell activation and target recognition by Vg9Vd2 T
cells4,6,7,36–39. The allosteric/sensor model anticipates that
intracellular interactions between the phosphoantigens domain
and the B30.2 domain of BTN3A1 induce conformational
changes of the transmembrane domain that are sensed by
Vg9Vd2 T cells, which cause their activation. The presentation
model predicts that BTN3A1 functions as an antigen-presenting
molecule for Vg9Vd2 T cells by extracellularly binding
phosphoantigens7. The two models are not mutually exclusive
and both models contemplate the possible contribution of a
second protein that has yet to be characterized4,40. In the
allosteric/sensor model, the unknown protein is expected to
facilitate intracellular interactions between phosphoantigens and
the B30.2 domain, whereas the unknown protein in the
presentation model is expected to facilitate the release of
endogenous phosphoantigens and the subsequent binding to
extracellular BTN3A1. It has been proposed that this hypothetical
transporter only intervenes when intracellular IPP exceeds a
critical threshold40. Our results unveils a new function of
BTN3A1 by showing its contribution to extracellular IPP
release in cooperation with ABCA1 and apoA-I. BTN3A1 is
physically associated with ABCA1 but is not associated with
apoA-I. BTN3A1 expression is not required to maintain the
association between ABCA1 and IPP; it is not correlated
with intracellular IPP concentrations and/or extracellular IPP
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Figure 6 | Regulation of ABCA1 and apoA-I expression via LXRa nuclear translocation. (a) Extracellular IPP release in DC left untreated or incubated
with 1mM ZA and/or simvastatin (SIM, 1 mM). Simvastatin abrogated ZA-induced extracellular IPP release. Bars represent the mean±s.e.m. of four
experiments (**Po0.01; ANOVA). (b) ABCA1 expression in experimental conditions as in a. ZA increased ABCA1 expression, whereas simvastatin showed
the opposite effect and abrogated ZA-induced ABCA1 upregulation. (c) apoA-I expression in experimental conditions, as shown in a. ZA increased
apoA-1 expression, whereas simvastatin exhibited the opposite effect and abrogated ZA-induced apoA-I upregulation. apoE was unaffected by ZA and/or
simvastatin treatments. (d) LXRa, LXRb and RXR levels were measured in nuclear extracts from DC incubated in the absence ( ) or presence (þ ) of
ZA and/or simvastatin. The LXRa activator TO-901317 (TO, 100nM for 24 h) was employed as a positive control. ZA increased LXRa protein levels and
this effect was antagonized by SIM. LXRb and RXR were unaffected by ZA and/or simvastatin treatment. b-tubulin and TBP are employed as
controls of equal protein loading as indicated. The blots are representative of one out of thee experiments (b–d). (e) Activity of Abca1 and apoA-I promoters
in the experimental conditions, as shown in d. ZA increased, whereas simvastatin decreased and antagonized the ZA-induced LXRa transcriptional activity
of Abca1 and apoA-I promoters. The bars represent the mean±s.e.m. of three experiments (**Po0.01; ***Po0.001; ANOVA). (f) Abca1 and apoA-I mRNA
levels in the experimental conditions, as shown in d. ZA increased the Abca1 and apoA-I mRNA levels, whereas simvastatin had the opposite effect and
antagonized ZA-induced upregulation. The bars represent the mean±s.e.m. of three experiments (**Po0.01; ***Po0.001; ANOVA). (g) Evaluation of
LXRa binding to LRE in the Abca1 promoter. ZA did not modify LXRa transcriptional activity, whereas IPP induced a dose-dependent upregulation of
LXRa-dependent Abca1 transcription. LXRa transcriptional activity in ZA-treated DC and TO-induced LXRa transcriptional activity are reported as positive
internal controls. The bars represent the mean±s.e.m. of four experiments (*Po0.001; ANOVA). ANOVA, analysis of variance.
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release and is not affected by ZA treatment. Btn3a1-silenced
ZA-treated DC are only marginally penalized in the ability to
release extracellular IPP compared with Abca1-silenced or
Btn3a1/Abca1-double silenced DC. Remarkably, ZA-treated
THP-1 cells and DCTHP1 accumulate higher amounts of
intracellular IPP than ZA-treated DC (approximately 1,500
versus 900 fmolml 1). In the absence of ABCA1 and despite
identical BTN3A1 expression, DCTHP1 fail to release extracellular
IPP and activate Vg9Vd2 T cells. These data indicate that ABCA1
serves a major role in extracellular IPP release from ZA-treated
DC; this function is ﬁne-tuned by one-to-one physical
interactions of ABCA1 with IPP, apoA-1 and BTN3A1. The
functional hierarchy of these molecules may be very different to
drive Vg9Vd2 T cell activation and target cell recognition once
IPP has been released in the microenvironment. In the absence of
ZA-treated cells, it is possible that IPP internalization in selected
cell subsets and the subsequent interaction with the intracellular
B30.2 domain of BTN3A1 play a more critical role than ABCA1
and apoA-I to induce Vg9Vd2 T cell activation.
We have deciphered two mechanisms that underlie
ZA-induced ABCA1 and apoA-1 upregulation. In vitro chroma-
tin immunoprecipitation (ChIP) experiments indicated that IPP
induces a dose-dependent LXRa binding to the LRE of the Abca1
promoter. The degree of DNA binding of puriﬁed LXRa
incubated with 500 pM IPP was similar to the degree of DNA
binding that was obtained in nuclear extracts of ZA-treated DC,
the intracellular IPP levels of which range between 500 and
1,000 pM. Thus, the ﬁrst mechanism is initiated by intracellular
IPP accumulation due to ZA-induced FPPS inhibition,
which causes LXRa activation, upregulation of Abca1/apoA-I
transcription and increased ABCA1 and apoA-I protein expres-
sion. IPP-induced LXRa activation in our model was highly
speciﬁc and cannot be reproduced with FPP or GGPP: the former
had no effect, whereas GGPP downregulated LXRa activation as
previously reported25. The antagonistic effect exerted by
simvastatin conﬁrmed the central role of IPP accumulation.
By inhibiting HMGCR upstream to FPPS, simvastatin prevents
ZA-induced intracellular IPP accumulation, ABCA1 and apoA-I
upregulation, extracellular IPP release and Vg9Vd2 T cell
activation. Unlike LXRa, DC express very low levels of LXRb41,
which remains unmodulated by ZA or simvastatin. Thus, the
LXRa/LXRb nuclear ratio is critical to ﬁne-tune not only
intracellular cholesterol concentrations in resting and activated
conventional T cells to satisfy their metabolic requirements27 but
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Figure 7 | The PI3K/AkT/mTOR pathway regulates IPP release via LXRa/Abca1 activation. (a) Targeting the Mev pathway ﬁne-tunes the
PI3K/Akt/mTOR signalling pathway. DC were left untreated or incubated with 1 mM ZA or simvastatin (SIM). ZA decreased, whereas simvastatin increased
the signalling activity of the PI3K/Akt/mTOR pathway. (b) DC were grown for 24 h in the absence ( ) or presence (þ ) of ZA (1 mM), the PI3K inhibitor
LY294002 (LY, 200 mM for 24 h ), the mTOR inhibitor rapamycin (RAP, 20 nM for 24 h). The LXRa activator TO-901317 (TO, 100nM for 24 h) was
included as positive control. PI3K/mTOR inhibitors increased LXRa nuclear translocation, such as ZA. Pooled data are obtained by densitometric analysis
with ImageJ software (http://imagej.nih.gov/ij/). The results are expressed as arbitrary units (n¼ 3) (*Po0.05; ANOVA). (c) Evaluation of LXRa binding
to LRE sequences in the Abca1 and apoA-1 promoters by ChIP assay. ZA, LY294002 and rapamycin increased Abca1 and apoA-1 promoters activity. The bars
represent the mean±s.e.m. of three experiments (***Po0.001; ANOVA). (d) Western blot analysis of ABCA1 and apoA-1 expression in experimental
conditions, as shown in b. PI3K and mTOR inhibition mimicked ZA treatment and upregulated ABCA1 and apoA-1 expression. b-tubulin and TBP were
employed as a control of equal protein loading, as indicated. All blots are representative of out the of three experiments. Pooled data are obtained by
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ANOVA). (e) Intracellular and extracellular IPP levels in DC after incubation in experimental conditions, as shown in b. As expected, PI3K/Akt/mTOR
inhibition only increased extracellular IPP. The bars represent the mean±s.e.m. of three experiments (**Po0.01, ***Po0.001; ANOVA). ANOVA, analysis
of variance.
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also to regulate extracellular IPP release in DC and the
subsequent activation of Vg9Vd2 T cells. It is also possible that
phosphoantigens are internalized from the microenvironment via
ﬂuid phase endocytosis o energy-dependent mechanism42,
especially when extracellular concentrations are much higher
than intracellular concentrations, as in the supernatants from
ZA-treated cells after removal of these cells. In this case, LXRa
activation, ABCA1, and apoA-I upregulation may be regulated by
internalization of extracellular IPP.
The second mechanism is dependent on ZA-induced inhibition
of the PI3K/Akt/mTOR signalling pathway26,30,43. This
mechanism has been described in tumour cells and associated
with anti-tumour ZA activity32,44. LXRa is also regulated by the
PI3K/Akt/mTOR pathway with different outcomes according to
the cell type26,45. In DC, ZA-induced inhibition of the PI3K/Akt/
mTOR signalling pathway increased LXRa-induced transcription
of Abca1 and apoA-I, which causes enhanced protein expression,
increased extracellular IPP release and Vg9Vd2 T cell activation.
Similar results were obtained by targeting the PI3K/Akt/mTOR
pathway with inhibitors other than ZA, which also upregulated
ABCA1 and apoA-1. These inhibitors, however, caused inferior
extracellular IPP release as they do not target the mevalonate
pathway and do not induce intracellular IPP accumulation.
The mechanism beyond ZA-induced PI3K/Akt/mTOR inhibi-
tion is likely due to intracellular isoprenoid deprivation instead of
IPP accumulation. ZA decreases GTP-bound Ras and downstream
Ras-regulated signalling pathways29,30. As activity of the PI3K/Akt/
mTOR pathway is upregulated by Ras, Ras deprenylation
is expected to downregulate PI3K/Akt/mTOR signalling and
increase LXRa activation28. Simvastatin also induces intracellular
isoprenoid deprivation and Ras deprenylation, but it unexpectedly
restored the activity of the PI3K/Akt/mTOR signalling in
ZA-treated DC. A possible explanation is that the concurrent ZA
and simvastatin treatments are so stressful to induce the expression
of ER-stress-related and UPR genes, which causes the recovery of
PI3K/Akt/mTOR signalling31.
Our results indicate that ABCA1 serves a pivotal role in
extracellular IPP release in cooperation with apoA-I and
BTN3A1. ABCA1 is upregulated by ZA via LXRa transcriptional
activation that is induced by intracellular IPP accumulation and
inhibition of the PI3K/Akt/mTOR signalling pathway. The
supernatants of ZA-treated DC contain sufﬁcient IPP concentra-
tions to induce Vg9Vd2 T cell activation also in the absence
of DC, but the manner in which soluble IPP engages Vg9Vd2
T cells remains to be determined (see Fig. 8 for a schematic
representation). Thus, Vg9Vd2 T cell activation can be regulated
not only with drugs that target the mevalonate pathway, such
as ZA and simvastatin but also with drugs that target the
PI3K/Akt/mTOR signalling pathway. Moreover, our data credit
ABCA1 with a novel immune function that is linked to the
activation of Vg9Vd2 T cells and contributes new perspectives
for understanding the relationship between lipid metabolism
and immune functions.
Methods
Chemicals. Plasticware for cell cultures was obtained from Falcon (Becton Dickinson,
Mountain View, CA). ZA was a gift from Novartis (Basel, Switzerland). Simvastatin
was purchased from Calbiochem (Billerica, MA). The electrophoresis reagents were
obtained from Bio-Rad Laboratories (Hercules, CA). The protein content of cell lysates
was assessed with the BCA kit from Sigma Chemical Co (St Louis, MO). If not
speciﬁed, all other reagents were purchased from Sigma Chemical Co.
Cells. Peripheral blood samples were drawn from healthy blood donors; the
samples were provided by the local Blood Bank (Fondazione Strumia). Peripheral
blood and bone marrow samples from multiple myeloma patients and B-cell
chronic lymphocytic leukaemia patients who carried mutated or unmutated
immunoglobulin heavy-chain variable regions were collected after informed
consent and approval by the local Institutional Review Board (Comitato Etico
Interaziendale A.O.U. Citta` della Salute e della Scienza di Torino—A.O. Ordine
Mauriziano—A.S.L. TO1) were received (DG 767/2015). After isolation on a Ficoll-
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Figure 8 | Mechanisms involved in IPP release from untreated and ZA-treated DC. (a): Mevalonate (Mev) pathway of untreated DC generates
isoprenoids (IPP: red circles; FPP/GGPP: yellow circles) and cholesterol (blue circles). Ras is prenylated in untreated DC (Ras-GTP) and causes the
activation of the PI3K/Akt/mTOR signalling pathway and suppression of LXRa transcriptional activity. ABCA1 and apoA-I expression is ﬁnalized to tune the
intracellular concentrations of cholesterol and other mevalonate pathway metabolites that were generated in physiological conditions. The supernatant
obtained from untreated DC is unable to induce the proliferation of Vg9Vd2 T cells as extracellular IPP concentrations are below a critical threshold.
(b) Farnesyl pyrophosphate synthase (FPPS) is inhibited in ZA-treated DC, which causes intracellular IPP accumulation (red circles), and isoprenoid
(yellow circles) and cholesterol (blue circles) deprivation. Intracellular IPP induces LXRa nuclear translocation (a), which enhances Abca1 and apoA-1 gene
transcription and upregulation of ABCA1 and apoA-I expression. Isoprenoid deprivation concurrently causes Ras deprenylation (Ras), which relieves the
inhibition operated by the PI3K/Akt/mTOR pathway on LXRa nuclear translocation (b). Thus, two mechanisms are operative in ZA-treated DC, which
causes upregulation of ABCA1 and apoA-1 expression and extracellular IPP and apoA-I release. The supernatant from ZA-treated DC contains sufﬁcient
amounts of IPP and apoA-I to induce the activation of Vg9Vd2 Tcells. The question mark in the right panel indicates that the mechanisms by which soluble
IPP released in the supernatant from ZA-treated DC induces Vg9Vd2 T cell activation remain to be elucidated.
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Hypaque density gradient, PBMC from healthy donors were kept unfractionated or
processed to purify CD14þ cells and generate different antigen-presenting cell
(APC) preparations. When PBMC from chronic lymphocytic leukaemia patients
contained less than 90% of CD19þ /CD5þ cells, cells were puriﬁed by negative
selection using a magnetic bead-activated cell sorting with a B cell Isolation Kit II
(Miltenyi Biotec, Bologna, Italy). Bone marrow mononuclear cells (BMMC) from
multiple myeloma and chronic lymphocytic leukaemia patients were left unfrac-
tionated to generate BMSC or were processed to purify CD138þ multiple mye-
loma cells. Control BMMC from healthy donors were purchased from Stem Cell
Technology (Peschiera Borromeo, Italy) to generate control BMSC. SKMM1, which
is a multiple myeloma cell line, THP-1 and U937 cells, which are two monocytic
leukaemia cell lines, and A549 cells, which is a non-small cell lung cancer cell line,
were provided by the ATCC (Manassas, VA). The standard culture medium was
RPMI 1640 (Euroclone, Milano, Italy) or HAM F12 medium (Euroclone) for A549
cells, which contain 10% fetal calf serum (FCS) (Euroclone), 2mM L-glutamine,
100Uml 1 penicillin, and 100mgml 1 streptomycin.
Commercial cell lines were authenticated by microsatellite analysis using the
PowerPlex kit (Promega Corporation, Madison, WI; last authentication:
December 2015). The cells were checked for Mycoplasma spp. contamination by
PCR every 3 weeks, and the contaminated cells were discharged.
Dendritic cell generation. CD14þ cells were puriﬁed using CD14 MicroBeads
and LS columns (Miltenyi Biotec) and incubated for 24 h in 24-well plates at
1 106 per ml in the presence or absence of 1 mM ZA. DC were generated as
previously reported3. Puriﬁed CD14þ cells were cultured in a standard culture
medium at 0.5–1.5 106 cells per ml that were supplemented with GM-CSF
(1000Uml 1) and IL-4 (500Uml 1) in ﬂat-bottomed 24-well plates for 24 h.
After 24 h, DC were left untreated (ZA-) or treated for an additional 24 h with
1 mM ZA (ZAþ ). To clear supernatants from any residual ZA, the DC were
washed after incubation with ZA and re-plated with fresh medium for an
additional 24 and 48 h (washed DC). DCTHP1 and DCU937 were generated with the
same procedure as previously described from THP-1 and U937 cells. The DC
phenotype was veriﬁed by cytoﬂuorimetric analysis as follows.
In selected experiments, supernatants obtained from different cell cultures were
collected and saved for a subsequent quantiﬁcation of intracellular IPP and
extracellular IPP levels and apoA-1 and apoE levels and to investigate their ability
to induce autologous Vg9Vd2 T cell proliferation.
Bone marrow stromal cells generation. BMSC were generated by seeding 1 106
BMMC/well in 24-well plates in a DMEM medium that was supplemented with
10% FCS and replaced every 3 days with fresh medium. After 4 days, non-adherent
cells were washed off and adherent cells—predominantly ﬁbroblast-like cells—were
grown in DMEM medium with 10% FCS until conﬂuence (2–3 weeks). The BMSC
phenotype was determined by cytoﬂuorimetric analysis as follows.
Immune-phenotyping. Phenotypic characterization of DC, Vg9Vd2 T cells,
myeloma cells and BMSC cells was performed with multicolour ﬂow cytometry.
The following anti-human monoclonal-antibody combinations were employed in
the characterization: (a) Vg9Vd2 T cells: anti-TCR Vg9 (clone B6, BD Pharmingen,
dilution 1/50), anti-CD3 (clone BW264/56, Miltenyi Biotec, dilution 1/11);
(b) DC: anti-CD80 (clone 2D10, Miltenyi Biotec, dilution 1/11), anti-CD86
(clone FM95, Miltenyi Biotec, dilution 1/11), anti-HLA-DR (clone AC122, Miltenyi
Biotec, dilution 1/11); (c) myeloma cells: anti-CD138 (clone 44F9, Becton
Dickinson, dilution 1/20); anti-CD38 (clone IB6, Becton Dickinson, dilution 1/20);
and (d) BMSC cells: anti-CD44 (clone G44-26, Becton Dickinson, dilution 1/20),
anti-CD105 (clone 266, Becton Dickinson, dilution 1/20), anti-CD11a
(clone HI111, Becton Dickinson, dilution 1/20). Three- and four-colour ﬂow
cytometry were performed with the appropriate combinations of ﬂuorescein
isothiocyanate (FITC), r-phycoerythrin-(PE), Tricolour-(Tri), Peridinin
Chlorophyll Protein Complex (PerCP) or allophycocyanin-(APC) conjugated
antibodies, a FACScan cell sorter, and CELLQuest software (Becton Dickinson).
Gating strategies are reported in the Supplementary Fig. 8.
Vc9Vd2 T cell activation and proliferation. PBMC were plated for 7 days at 106
cells per ml in 96-wells round-bottomed plates at 37 C in a humidiﬁed atmosphere
of 5% CO2 in air in the presence of 10 IUml 1 IL-2 (Eurocetus, Milano, Italy) and
1 mM ZA (kindly provided by Novartis Pharma, Origgio, Italy). The standard
culture medium was RPMI 1640 (Eurobio, Les Ulis, France), containing 10% FCS
(Mascia Brunelli, Milano, Italy), 2mM L-glutamine (Eurobio, Les Ulis, France),
100Uml 1 penicillin (Eurobio, Les Ulis, France) and 100mgml 1 streptomycin
(Eurobio, Les Ulis, France)3. Total counts of viable Vg9Vd2 T cells on day 7 were
evaluated by multiplying total counts of viable cells per well, identiﬁed with the
trypan blue staining assay, by the percentage of Vg9Vd2 T cells identiﬁed by ﬂow
cytometry46.
Quantiﬁcation of intracellular and extracellular IPP. After 24 h culture, 1 106
cell per ml were incubated for another 24 h with 1 mCi of [3H]acetate
(3,600mCimmol 1; Amersham International, Piscataway, NJ) to measure the
intracellular IPP synthesis. 300ml cells lysate or culture supernatant was diluted 1:2
into an ice-cold acetonitrile solution containing 100mM NaVO4 and 250mM NaF,
and centrifuged at 1,200g for 5min at 4 C. After lyophilization under vacuum,
samples were resuspended in 20 ml dimethylhexylamine and separated by thin layer
chromatography (TLC; LK6D Whatmann silica gel Merck, Darmstadt, Germany),
using 1:1 solution of 50% methanol/0.8M ammonium formate, pH 7.4, containing
2mM dimethylhexylammine as running buffer. Gels were exposed to an
iodine-saturated atmosphere for 2 h, and the spot that corresponds to IPP was
quantiﬁed by liquid scintillation counting (UltimaGold; PerkinElmer, Waltham,
MA). According to the titration curve, the results are expressed as fmolesml 1 for
intracellular IPP or pmolesml 1 for extracellular IPP.
Efﬂux of exogenous [14C]-IPP. To measure the efﬂux of an exogenous
pulse of IPP, 1 106 cell ml 1 were labelled for 1 h with 0.02 mCi of [14C] IPP
(50mCimmol 1; Amersham International),washed ﬁve times with PBS and left
for 24 h in fresh medium. After this incubation time, supernatants were collected
and underwent the same analytical process that was used to measure endogenously
generated extracellular IPP. The amount of [14C]IPP that was present in the culture
medium at t0 is considered to be 100%; the amount of [14C]IPP that was measured
after incubation is expressed as a percentage relative to the amount measured at t0.
MALDI-TOF/MS analysis. Fifty ml of the culture medium of 1 106 CD14þ or
DC were resolved by 12% SDS–PAGE, then stained using colloidal Coomassie
brilliant blue (18% v-v ethanol, 15% w-v ammonium sulphate, 2% v-v phosphoric
acid, 0.2% w/v Coomassie brilliant blue G-250). Gel slices from Coomassie-stained
gels aligned to the recombinant human apoE or apoA-I, which were employed as
standards, were excised and digested as previously described47. Gel slices were
destained in 50% v-v acetonitrile in 5mM ammonium bicarbonate, dried using
pure acetonitrile and rehydrated for 45min at 4 C with digestion buffer that
contains 10 ng ml 1 trypsin in 5mM ammonium bicarbonate. Digestion proceeded
overnight at 37 C. The mass spectrometry analysis of peptides was performed
using a matrix-assisted laser desorption ionization-time-of-ﬂight/mass
spectrometry device (MALDI micro MX; Waters, Milford, MA, USA) that was
equipped with a delayed extraction unit that operated in reﬂectron mode. The
peptide solution was prepared with equal volumes of saturated a-cyano-4-
hydroxycinnamic acid solution in 40% v/v acetonitrile-0.1% v/v triﬂuoroacetic acid.
The MALDI-TOF was calibrated with a mix of PEG (PEG 1000, 2000 and 3000
at a ratio of 1:2:2) and mass spectra were acquired in the positive-ion mode.
Peak lists were generated by ProteinLynx Global Server 2.2.5 (Waters, Milford,
MA, USA) using the following parameters: external calibration with lock mass
using a mass of 2465.1989Da for ACTH (adrenocorticotropic hormone),
background subtract type adaptive that combined all scans, and de-isotoping
with a threshold of 1%. The 25 most intense masses were employed for database
searches against the SWISSPROT database using the free search program
MASCOT (http://www.matrixscience.com). The following parameters were
employed in the searches: taxa Homo sapiens, trypsin digest, one missed cleavage
by trypsin, methionine oxidation as variable modiﬁcation and allowed maximum
error of 100 p.p.m.
Western blotting. The cells were lysed in a MLB buffer (125mM Tris-HCl,
750mM NaCl, 1% v/v NP40, 10% v/v glycerol, 50mM MgCl2, 5mM EDTA,
25mM NaF, 1mM NaVO4, 10mgml 1 leupeptin, 10mgml 1 pepstatin,
10 mgml 1 aprotinin, 1mM phenylmethylsulphonyl ﬂuoride, pH 7.5), sonicated
and centrifuged at 13,000g for 10min at 4 C. Plasma-membrane-associated
proteins were isolated by the biotinylation method, using the Surface Protein
Isolation Kit (Fisher Scientiﬁc Inc., Rockford, IL)48. Twenty microgram of proteins
from cell lysates or biotinylated extracts were subjected to western blotting and
probed with the following antibodies: anti-ABCA1 (HJI, Abcam, Cambridge,
UK, dilution 1/500), anti-ABCA2 (ab91571, Abcam, dilution 1/250), anti-ABCB1
(C219, Novus Biologicals, Littleton, CO, dilution 1/250), anti-ABCC1 (IU2H10,
Abcam, dilution 1/100), anti-ABCC2 (M2 III-6, Abcam, dilution 1/50),
anti-ABCC3 (sc-5776, Santa Cruz Biotechnology Inc., Santa Cruz, CA,
dilution 1/500), anti-ABCC4 (ab77184, Abcam, dilution 1/250), anti-ABCC5
(sc-5781, Santa Cruz Biotechnology Inc., dilution 1/500), anti-ABCC6 (ab54826,
Abcam, dilution 1/500), anti-ABCG1 (sc-11150, Santa Cruz Biotechnology Inc.,
dilution 1/1,000), anti-ABCG2 (sc-25882, Santa Cruz Biotechnology Inc., dilution
1/100), anti-ABCG4 (ab101528, Abcam, dilution 1/250), anti-ABCG5 (EPR6203,
Abcam, dilution 1/500), anti-ABCG8 (ab126493, Abcam, dilution 1/500),
anti-SR-BI (NB400-104, Novus Biologicals, dilution 1/1,000), anti-BTN3A1
(25221-1-AP, Proteintech, Chicago, IL, dilution 1/500), anti-apoA-I (SAB1104904,
Sigma Chemical Co., dilution 1/1,000), anti-apoE (AV54283, Sigma Chemical Co.,
dilution 1/1,000), anti-PiT-1/SLC20A1 (ab58181, Abcam, dilution 1/200),
anti-PiT-2/SLC20A2 (ab155259, Abcam, dilution 1/200), anti-NPT2A/SLC34A1
(ab151129, Abcam, dilution 1/500), anti-Naþ /Kþ -ATPase (M7-PB-E9, Sigma
Chemical Co., dilution 1/2,000), anti-Naþ /Hþ exchanger 1/NHE1 (sc-136239,
Santa Cruz Biotechnology Inc., dilution 1/500), anti-Cl-/HCO3- transporter/
SLC4A1 (EPR1426, Abcam, dilution 1/1,000), anti-phospho(Ser473)Akt
(6F5, Millipore, Billerica, MA, dilution 1/1,000), anti-Akt (SKB1, Millipore,
dilution 1/500), anti-phospho(Thr389)-p70 S6K (#9205, Cell Signalling
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Technology, Danvers, MA, dilution 1/1,000), anti-phospho(Thr421/Ser424)-p70
S6K (#9204, Cell Signalling Technology, dilution 1/1,000), and anti-p70 S6K
(#9202, Cell Signalling Technology, dilution 1/1,000). Anti-b-tubulin (sc-5274,
Santa Cruz Biotechnology Inc., dilution 1/1,000) and anti-pancadherin (sc-1499,
Santa Cruz Biotechnology Inc., dilution 1/500) were employed as a control of equal
protein loading in whole cell and plasma-membrane extracts, followed by a
peroxidase-conjugated secondary antibody. The proteins were detected by
enhanced chemiluminescence (Bio-Rad Laboratories).
In the co-immunoprecipitation assays, 100mg of proteins from biotinylated
plasma-membrane extracts, which were prepared as previously described, were
immunoprecipitated with the anti-BTN3A1 antibody, using the PureProteome
protein A and protein G Magnetic Beads (Millipore). The immunoprecipitated
proteins were separated by SDS–PAGE and probed with the anti-ABCA1 or
apoA-I antibodies. An anti-pancadherin antibody was employed as the control for
equal plasma-membrane protein loading.
To evaluate LXRa, LXRb and RXR nuclear translocations, nuclear extracts
were prepared using the Nuclear Extract kit (Active Motif, La Hulpe, Belgium).
Ten microgram of nuclear proteins were resolved by SDS–PAGE and probed with
anti-LXRa (61175, Active Motif, dilution 1/500), anti-LXRb (ABN65, Millipore,
dilution 1/500), anti-RXR (ab24363, Abcam, dilution 1/2,000) antibodies or with
an anti-TFIID/TATA box-binding protein (TBP) antibody (58C9, Santa Cruz
Biotechnology Inc., dilution 1/250) as the equal protein loading control.
The images of uncropped gels reported in main ﬁgures and Supplementary
Figures are shown in Supplementary Figs 9 and 10.
Abca1 and Btn3a1 silencing. Two 105 DC were transfected with Accell Human
siRNA ABCA1, Accell Human BTN3A1 siRNA or 19–25 nucleotide non-targeting
scrambled siRNAs (from Thermo Scientiﬁc Open Biosystems, Waltham, MA) per
the manufacturer’s instructions. The efﬁcacy of silencing was veriﬁed by western
blotting, as previously described.
Proximity ligation assay. The presence of ABCA1-BTN3A1 interactions was
assessed with the PLA method using the DuoLink In Situ kit (Sigma Chemical Co.)
per the manufacturer’s instructions. A total of 1 104 cells were seeded on sterile
coverglass, washed with PBS, ﬁxed for 10min at room temperature with 4% v/v
paraformaldehyde, washed twice with PBS, and incubated 30min at 37 C in a
humidiﬁed chamber with 40 ml of the kit-provided Blocking solution. A mouse
anti-human ABCA1 (HJI, Abcam) and rabbit anti-human BTN3A1 (HPA012565,
Sigma Chemical Co.) antibodies were added at 1:50 ﬁnal dilution. Samples were
maintained at 4 C overnight. Slides were washed once with the Wash buffer A for
5min at room temperature, and incubated 1 h at 37 C with the respective PLA
probes diluted 1:5 into 40ml diluent antibody solution. Samples were washed twice
with wash buffer A for 5min at room temperature and incubated for 30min at
37 C with 40ml ligation solution diluted 1:5 into RNAse/DNAse-free water and
containing 25mU ligase. After two washes at the rate of 2min per each at room
temperature, ampliﬁcation was performed by adding 40 ml ampliﬁcation solution
that was diluted 1:5 into RNAse/DNAse-free water and contained 125mU
polymerase. Samples were maintained for 2 h at 37 C, washed twice with undiluted
wash buffer B for 10min, once with wash buffer B, diluted 1:100 for 1min,
and mounted with the DuoLink In Situ Mounting medium, which contained
40 ,5-diamidino-2 phenylindole dyhydrochloride (DAPI) to counterstain cells’
nuclei. Cells were examined using a Leica TCS SP2 AOP confocal laser-scanning
microscope (Leica Microsystem, Wetzlar, Germany). A minimum of ﬁve ﬁelds
were examined for each experimental condition.
Crosslinking assay. Crosslinking of apoA-I to cell surface proteins was performed
as previously reported20. After labelling for 2 h at 37 C with 5 mgml 1
[125I]-apoA-I and chemically crosslinking with dithiobis(succinimidyl propionate)
(DSP), cells were lysed and subjected to immunoprecipitation with an anti-apoA-I
antibody (SAB1104904, Sigma Chemical Co., dilution 1/100). Samples were
resolved by SDS–PAGE, and blotted proteins were detected by autoradiography
(Kodak BioMax MR-1, PerkinElmer).
IPP-ABCA1 interaction. IPP-ABCA1 interaction was measured in the cells
labelled with 1 mM [14C]-IPP for 1 h. After extensively washing (ﬁve washing steps
of 5min with PBS) to remove any traces of residual [14C]-IPP in the extracellular
medium, the cells were grown in fresh medium for 1 h and ﬁxed with DSP.
The surface proteins were isolated with the Surface Protein Isolation Kit
(Fisher Scientiﬁc Inc. A total of 500mg of surface proteins were subjected to
immunoprecipitation with an anti-ABCA1 antibody (HJI, Abcam, dilution 1/50).
As an internal control, cells were incubated 5min with 2mM dithiothreitol, and
the biotinylated extracts were subjected to limited digestion with 10 mgml 1
trypsin, as reported21,22. Immunopuriﬁed ABCA1 was resolved by SDS–PAGE, and
run in duplicate on the same gel. One part of the gel was probed with the anti-
ABCBA antibody; the second part was dried and subjected to autoradiography to
visualize the [14C]-IPP signal.
Quantitative real time-PCR and PCR array. Total RNA was reverse-transcribed
using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories). The qRT-PCR
was performed with the IQ SYBR Green Supermix (Bio-Rad). The same cDNA
preparation was employed to quantify the genes of interest and the housekeeping
gene S14. The primer sequences, which were designed using the qPrimerDepot
database (http://primerdepot.nci.nih.gov/), were as follows: for Abca1:
50-CAGAGCTCACAGCAGGGAC-30; 50-CTTCTCCGGAAGGCTTGTC-30 ; for
apoA-I: 50-CCCAGTTGTCAAGGAGCTTT-30 , 50-TGGATGTGCTCAAAG
ACAGC-30 ; for S14: 50-CGAGGCTGATGACCTGTTCT-30 ; 50-GCCCTCTC
CCACTCTCTCTT-30 . The relative quantiﬁcation was performed by comparing
each PCR product with the housekeeping PCR product S14, using the Bio-Rad
Software Gene Expression Quantitation (Bio-Rad). PCR arrays were generated
using 1 mg cDNA and Human Unfolded Protein Response Plus RT2 Proﬁler
PCR Array (Bio-Rad Laboratories) according to the manufacturer’s instructions.
Data analysis was performed using the PrimePCR Analysis Software
(Bio-Rad Laboratories).
Chromatin Immunoprecipitation. ChIP samples were prepared as described by
Campia et al.49, using a ChIP-tested anti-LXRa antibody (61175, Active Motif,
dilution 1/50). The putative Liver X Receptor Response Element (LRE) sites on
Abca1 and apoA-I human promoters were validated with the Matinspector
Software (https://www.genomatix.de/matinspector.html). Primer sequences were as
follows: for Abca1 promoter: 50-GGAGAGCACAGGCTTTGACC-30 ; 50-CTCTC
GCGCAATTACGGG-30; for apoA-I promoter: 50-AACTGCCCACACACTC
CCAT-30 ; 50-TCCTTCTCGCAGTCTCTAAGCA-30 . Primers used as negative
internal controls for a nonspeciﬁc 10 000 bp upstream sequence, were as follows:
50-GTGGTGCCTGAGGAAGAGAG-30 and 50-GCAACAAGTAGGCACAA
GCA-30 . The immunoprecipitated products were ampliﬁed by qRT-PCR.
In in vitro ChIP experiments, total DNA from 1 106 DC was extracted using
the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma Chemical Co.),
sonicated, incubated with 1 ng of recombinant human LXRa protein (Abcam),
immunoprecipitated with the anti-LXRa antibody and processed as previously
described.
Activity of plasma-membrane-associated transporter and channels. Plasma-
membrane vesicles enriched for ATP-binding cassette transporters were prepared
as detailed elsewhere with minor modiﬁcations50. Cells were washed with Ringer’s
solution (148.7mM NaCl, 2.55mM K2HPO4, 0.45mM KH2PO4, 1.2mM MgSO4;
pH 7.4), lysed on crushed ice with lysis buffer (10mM Hepes/Tris, 5mM EDTA,
5mM EGTA, 2mM dithiothreitol; pH 7.4) supplemented with 2mM
phenylmethylsulfonyl ﬂuoride, 1mM aprotinin, 10 mgml 1 pepstatin, 10 mgml 1
leupeptin, and subjected to nitrogen cavitation at 1200 p.s.i for 20min. Samples
were centrifuged at 300g for 10min, diluted 1:4 in the pre-centrifugation
buffer (10mM Tris/HCl, 25mM sucrose; pH 7.5), overlaid on a sucrose cushion
(10mM Tris/HCl, 35% w/v sucrose, 1mM EDTA; pH 7.5) and centrifuged at
14,000g for 10min. The interface was collected, diluted 1:5 in the centrifugation
buffer (10mM Tris/HCl, 250mM sucrose; pH 7.5) and subjected to a third
centrifugation at 100,000 g for 45min. The vesicle pellet was resuspended in
0.5ml centrifugation buffer and stored at  80 C until the use, after the
quantiﬁcation of the protein content. Proteins were extracted by non-denaturing
immunoprecipitation using the previously indicated antibodies. The ATPase
activity of immunopuriﬁed ABCA1, ABCA2, ABCB1, ABCC1, ABCC3, ABCC4,
ABCG1, ABCG2 and ABCG4 was measured with a spectrophotometric method51.
Samples (containing 25 mg protein) were incubated for 30min at 37 C with 50 ml of
the reaction mix (25mM Tris/HCl, 3mM ATP, 50mM KCl, 2.5mM MgSO4,
3mM dithiothreitol, 0.5mM EGTA, 2mM ouabain, 3mM NaN3; pH 7.0). In each
set of experiments, a blank containing 0.5mM Na3VO4 was included52. The
reaction was stopped by adding 0.2ml ice-cold stopping buffer (0.2% w/v
ammonium molybdate, 1.3% v/v H2SO4, 0.9% w/v SDS, 2.3% w/v trichloroacetic
acid, 1% w/v ascorbic acid). After a 30min incubation at room temperature, the
absorbance of the phosphate hydrolyzed from ATP was measured at 620 nm, using
a Packard EL340 microplate reader (Bio-Tek Instruments, Winooski, MA). The
absorbance was converted into mmol hydrolyzed phosphate per min per mg
proteins, according to the titration curve previously prepared. The activity of
PiT-1/SLC20A1 and PiT-2/SLC20A2 (ref. 50), and Naþ /Kþ -ATPase53 were
spectrophotometrically measured. The results are expressed as nmoles of
hydrolysed phosphate per min per mg proteins according to the previously
prepared titration curve. The NHE1 and SLC4A1 activities were ﬂuorimetrically
measured54,55, and the results are expressed as DpHi/min and arbitrary units,
respectively.
Statistical analysis. The results are expressed as the mean±s.e.m. Differences
between the groups were evaluated with a one-way analysis of variance, a Wilcoxon–
Mann–Whitney non-parametric test for paired or unpaired samples as appropriate
and was considered to be statistically signiﬁcant for P values o0.05. Correlation
analyses were performed with the non-parametric Spearman Rank Order test with a
cutoff P valueo0.05. The GraphPad software was used for the statistical analyses; its
symbology has been adopted to deﬁne the statistical signiﬁcance (ns¼ P40.05;
*Po0.05; **Po0.01; ***Po0.001; ****Po0.0001). The sample size was calculated
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with the G*Power software (www.gpower.hhu.de), with the setting Po0.05 as the
signiﬁcance level and 0.80 as the power of the study.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the paper and its Supplementary Information ﬁles.
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